FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference

Clin Chem Lab Med. 2020 Oct 25;58(11):e267-e269. doi: 10.1515/cclm-2020-0460.

¹ AP-HP, Department of Functional Explorations, Necker Enfants Malades Hospital, Paris-Centre University, Paris Cedex, France.
² AP-HP, Department of Endocrinology and Diabetology for children and Department of Adolescent Medicine, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Filière OSCAR and Platform of Expertise for Rare Diseases Paris-Sud, Bicêtre Paris-Saclay Hospital, Paris Saclay University, Le Kremlin-Bicêtre, France.

No abstract available

Keywords: FGF23; X-linked hypophosphataemia (XLH); burosumab; immunoassay; interference.

Publication types